# AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS

> **NCT05195645** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 21 (actual)

## Conditions studied

- Myocarditis

## Interventions

- **DRUG:** Abatacept 250 MG

## Key facts

- **NCT ID:** NCT05195645
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-04
- **Primary completion:** 2024-03-05
- **Final completion:** 2025-09-15
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05195645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05195645, "AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05195645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*